CLINICAL TRIALS AND OBSERVATIONS Unique features of primary myelofibrosis in Chinese
نویسندگان
چکیده
1MDS and MPN Centre, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China; 2Imperial College of Medicine, Hammersmith Hospital, London, United Kingdom; and 3Department of Pathology and 4State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
منابع مشابه
CLINICAL TRIALS AND OBSERVATIONS Brief report Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis
1Ospedali Riuniti di Bergamo, Bergamo, Italy; 2University of Cologne, Cologne, Germany; 3Ospedale di Varese, Varese, Italy; 4University of Pavia, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Policlinico San Matteo, Pavia, Italy; 5University of Padua, Padua, Italy; 6University of Florence, Florence, Italy; 7Medical University of Vienna, Vienna, Austria; 8Institute of Pathology...
متن کاملMolecular Pathogenesis and Clinical Significance of Driver Mutations in Primary Myelofibrosis: A Review
Primary myelofibrosis (PMF) is a rare chronic BCR-ABL1-negative myeloproliferative neoplasm characterized by progressive bone marrow fibrosis, inefficient hematopoiesis, and shortened survival. The clinical manifestations of PMF include splenomegaly, consequent to extramedullary hematopoiesis, pancytopenias, and an array of potentially debilitating constitutional symptoms. The diagnosis is base...
متن کاملClinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis.
We studied the impact of driver mutations of JAK2, CALR, (calreticulin gene) or MPL on clinical course, leukemic transformation, and survival of patients with primary myelofibrosis (PMF). Of the 617 subjects studied, 399 (64.7%) carried JAK2 (V617F), 140 (22.7%) had a CALR exon 9 indel, 25 (4.0%) carried an MPL (W515) mutation, and 53 (8.6%) had nonmutated JAK2, CALR, and MPL (so-called triple-...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation
JAK2 V617F mutation recently was identified as a pathogenic factor in typical chronic myeloproliferative diseases (CMPD). Some forms of myelodysplastic syndromes (MDS) show a significant overlap with CMPD (classified as MDS/MPD), but the diagnostic assignment may be challenging. We studied blood or bone marrow from 270 patients with MDS, MDS/MPD, and CMPD for the presence of JAK2 V617F mutation...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Thrombocythemia and polycythemia in patients younger than 20 years at diagnosis: clinical and biologic features, treatment, and long-term outcome
Sixty-four patients < 20 years of age, investigated for a suspicion of Philadelphianegative myeloproliferative disease (MPD), were retrospectively evaluated to characterize the different forms and to examine the treatments used and longterm outcome. JAK2 mutations, endogenous erythroid colony growth, and clonality were investigated in 51 children. Mutations of thrombopoietin, the thrombopoietin...
متن کامل